Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647)

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 11, 2001, Pages 3104-3108

  Muller Serieys, C ^a   Soler, P ^a   Cantalloube, C ^a   Lemaitre, F ^a   Hai Pham Gia, ^a   Brunner, F ^a   Andremont, A ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

KETOLIDE; TELITHROMYCIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BRONCHUS MUCOSA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG PENETRATION; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; LUNG ALVEOLUS MACROPHAGE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BRONCHI; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; EPITHELIAL CELLS; EPITHELIUM; HUMANS; KETOLIDES; LUNG; MACROLIDES; MACROPHAGES, ALVEOLAR; MALE;

EID: 0034774476     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.11.3104-3108.2001     Document Type: Article

References (22)

1. Antipneumoccal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin)
2. In vitro activity of ketolides against mycoplasmas
3. Bresistance phenotype
4. Intrapulmonary disposition of clarithromycin and crythromycin
5. Single dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciproflaxacin, and cefuroxime in volunteer subjects
6. Cell numbers and cell characteristics of the normal human lung
7. Antibiotic pharmacokinetic considerations in pulmonary infections
8. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA
9. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
10. Practical considerations and guidelines for the management of community-acquired pneumonia
11. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis
12. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy
13. The pharmacokinetics of azithromycin and their clinical significance
14. Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients
15. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses
16. Susceptibilities of penicillin-and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
17. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany
18. Relationships of high tissue concentrations of azithromycin to bacteriocidal activity and efficacy in vivo
19. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
20. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers
21. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
22. Interactions between HMR 3647, a new ketolide and human polymorphonuclear neutrophils